Investigation of the effects of intravenous fluid therapy and Imatinib administration in a human intravenous lipopolysaccharide (LPS) model of sepsis.
Investigation of the effects of intravenous fluid therapy and Imatinib administration in a human intravenous lipopolysaccharide (LPS) model of sepsis.
批准号:
MR/X001660/1
负责人:
Ross McMullan
金额:
$37.91万
依托单位国家:
英国
项目类别:
Fellowship
财政年份:
2022
资助国家:
英国
项目状态:
未结题
起止时间:
2022 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The problem:Sepsis is a common, out-of-control immune response to infection which often causes people to become critically ill and require admission to intensive care. Sepsis is a leading cause of death world-wide. Red blood cells carry oxygen around the body through small blood vessels. Sepsis causes blood flow through the blood vessels to become abnormal, so that some areas may not receive enough blood flow and hence not enough oxygen. Without oxygen, cells in the body stop working and die, causing vital organs, such as the kidneys and heart, to fail. Ultimately, this organ failure leads to critical illness and death. Sepsis also causes damage to special cells, called endothelial cells, which form the inner lining of blood vessels. As a result, the blood vessels become "leaky", allowing fluid to move from the blood vessels into surrounding areas. This leaked fluid causes swelling of the areas surrounding the blood vessels, making it even harder for oxygen to reach the cells where it is needed. A key treatment for sepsis is to give fluids intravenously, that is directly into a vein, in order improve blood flow around the body. However, there is evidence that too much fluid may be harmful, perhaps even making patients with sepsis more likely to die. Giving fluid may cause more damage to the lining of blood vessels, thereby making swelling worse. This additional swelling makes it even more difficult for oxygen to be delivered to where it is required, resulting in the failure of multiple organs. It is clearly very important to establish the effects of intravenous fluid on blood vessels and blood flow in people with sepsis, as it may be either helping or causing harm. It is also important to find out if any drugs can protect the blood vessels from damage in the first place or control the immune response to infection.The Research Proposal: We will give healthy volunteers a substance derived from bacteria, known as lipopolysaccharide (LPS), by injection into a vein. LPS has been safely and reliably given to hundreds of people over several decades. It causes a predictable and very mild sepsis-like state for a few hours, similar to a mild flu. Symptoms can be treated with Paracetamol, although this is usually not required. People who are given LPS recover fully within 24 hours or less. This will be carried out in a fully equipped medical research centre with trained intensive care doctors. We will use a specialised camera that will allow us to see the small blood vessels under the tongue. We will measure blood flow and look at blood vessels before and up to 24 hours after giving LPS. We will also take blood samples at intervals to look at the immune response to receiving LPS.After giving LPS, some volunteers will be given intravenous fluids, and some not. By comparing the two groups, we can see what effect, if any, intravenous fluid has on blood flow, on small blood vessels and on the immune system. As well as intravenous fluids, we also plan to investigate the effect of a drug called imatinib, a very safe drug used for decades to treat a type of leukaemia. A number of studies have shown that imatinib may also help protect endothelial cells from damage. Some of the volunteers will be given imatinib and some will not. Again, by comparing the blood flow, blood vessels and blood markers of the immune response, we will be able to see if imatinib has any beneficial effects.Applications and Benefits:Through this study, we hope to establish the effects on small blood vessels and on the immune system by giving LPS to healthy human volunteers in order to produce a mild sepsis-like state. We also aim to understand the effects of intravenous fluid and imatinib treatment in people with this sepsis-like condition. Our findings will help us to design future clinical trials to see if different ways of giving fluid, or imatinib, can help real world patients with sepsis. This project will lead to better treatment of sepsis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
Dynamic Credit Rating with Feedback Effects
-
批准号:--
-
项目类别:外国学者研究基金项目
-
资助金额:--
-
批准年份:2024
-
负责人:Christian Martin Hilpert
-
依托单位:
NPM1表观重塑巨噬细胞代谢及修复表型在心肌缺血损伤中的调控作用
-
批准号:82371825
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:占贞贞
-
依托单位:
内源性蛋白酶抑制剂SerpinA3N对缺血性脑卒中后血脑屏障的保护作用及其表达调控机制
-
批准号:82371317
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:万杰清
-
依托单位:
儿童期受虐经历影响成年人群幸福感:行为、神经机制与干预研究
-
批准号:32371121
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:孔风
-
依托单位:
水环境中新兴污染物类抗生素效应(Like-Antibiotic Effects,L-AE)作用机制研究
-
批准号:21477024
-
项目类别:面上项目
-
资助金额:86.0万元
-
批准年份:2014
-
负责人:李丹
-
依托单位:
动态整体面孔认知加工的认知机制的研究
-
批准号:31070908
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:葛列众
-
依托单位:
磁性隧道结的势垒及电极无序效应的研究
-
批准号:10874076
-
项目类别:面上项目
-
资助金额:34.0万元
-
批准年份:2008
-
负责人:胡安
-
依托单位:
抗抑郁剂调控细胞骨架蛋白的功能研究
-
批准号:30472018
-
项目类别:面上项目
-
资助金额:16.0万元
-
批准年份:2004
-
负责人:杨红菊
-
依托单位: